- Benson Hill Inc (NYSE:BHIL) reported second-quarter FY22 sales growth of 179% year-on-year, to $110.75 million, beating the consensus of $84.38 million.
- Segment Revenue: Ingredients jumped 312% Y/Y to $93.5 million, and the Fresh segment rose 1% to $17.1 million.
- The gross profit for the quarter was $5.6 million with a profit margin of 5%.
- The operating loss for the quarter widened to $(28.9) million.
- The company held $209.9 million in cash and equivalents as of June 30, 2022.
- EPS loss of $(0.15) beat the analyst consensus of $(0.21).
- Outlook: Benson Hill currently sees consolidated 2022 revenues of $340 million – $400 million (consensus $343.58 million).
- BHIL sees FY22 Ingredients segment sales of $275 million – $325 million, above the previous guidance of $250 million – $275 million.
- The company expects FY22 Fresh segment sales of $65 million – $75 million.
- Price Action: BHIL shares are trading higher by 0.45% at $3.33 on the last check Monday.
Sanofi Announced CHMP Recommended Approval of Beyfortus for Prevention of RSV Disease in Infants
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus® (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
